1 / 20

TOC - Natural Killer (NK) Cell Therapeutics Market

The global NK cell therapeutics market is expected to reach $5,676.1 million in 2032 from $297.2 million in 2024 at a CAGR of 44.59% during the forecast period 2024-2032

bisreports
Download Presentation

TOC - Natural Killer (NK) Cell Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Natural Killer (NK) Cell Therapeutics Market - A Global and Regional Analysis Table of Content GLOBAL NK CELL THERAPEUTICS MARKET Focus on NK Cell Therapy Type, Indication, Country, Pipeline Analysis, and Competitive Landscape Analysis and Forecast: 2022-2032 June 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL NK CELL THERAPEUTICS MARKET Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered, whether for sale or otherwise, to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary ........................................................................ 21 1.Market ...................................................................................... 29 1.1 Product Definition ............................................................................................ 30 1.2 Inclusion and Exclusion Criteria .................................................................... 30 1.3 Market Scope ................................................................................................... 30 1.3.1Key Questions Answered ........................................................................... 32 1.4 Research Methodology ................................................................................... 32 1.4.1Global NK Cell Therapeutics Market: Research Methodology ................ 32 1.4.2Primary Data Sources ................................................................................. 33 1.4.3Secondary Data Sources ............................................................................ 34 1.5 Market Estimation Model................................................................................. 35 1.6 Criteria for Company Profiling ........................................................................ 36 1.7 Market Overview .............................................................................................. 37 1.7.1Introduction ................................................................................................. 37 1.7.2Evolution of NK Cell Therapeutics ............................................................. 39 1.7.3Types of NK Cell Therapeutics ................................................................... 40 1.7.4Source of NK Cell Therapeutics ................................................................. 41 1.7.5Mechanism of Action: NK Cell Therapies .................................................. 41 1.7.5.1 Application of NK Cell Therapeutics in Disease Areas...................................... 43 1.7.5.1.1Cancer ...................................................................................................................... 43 GLOBAL NK CELL THERAPEUTICS MARKET 1.7.5.1.2Acute Infectious Disease ......................................................................................... 44 1.7.6Role of NK Cell Therapeutics in COVID-19 ................................................ 44 1.7.7Comparison between Car T-Cell Therapy and NK Cell Therapy .............. 45 1.7.8Advantages and Limitations of NK Cell Therapeutics ............................. 45 1.7.9Current Market Size and Growth Potential, $Million, 2022-2032 ............. 46 1.7.10COVID-19 Impact on Global NK Cell Therapeutics Market ...................... 47 1.7.10.1 Overview .......................................................................................................... 47 1.7.10.2 Research and Clinical Development Interruption in Global NK Cell Therapeutics Market ........................................................................................ 47 3 All rights reserved at BIS Research Inc.

  4. 2.Pipeline Analysis ...................................................................... 49 2.1 Global NK Cell Therapeutics Market Pipeline Analysis ................................ 50 2.2 Probable Potential First Entrants to Global NK Cell Therapeutics Market ............................................................................................................... 56 2.2.1Overview ...................................................................................................... 56 2.2.2AFM13 ........................................................................................................... 57 2.2.2.1 Product Profile.................................................................................................. 57 2.2.2.2 AFM13 Phase II Study Design ......................................................................... 58 2.2.3MG4101 ......................................................................................................... 59 2.2.3.1 Product Profile.................................................................................................. 59 2.2.3.2 MG4101 Phase II Study Design ....................................................................... 60 2.2.4GTA002 (oNKord) ........................................................................................ 61 2.2.4.1 Product Profile.................................................................................................. 61 2.2.4.2 GTA002 (oNKord) Phase II Study Design ........................................................ 62 2.2.5TAK-007 ........................................................................................................ 64 2.2.5.1 Product Profile.................................................................................................. 64 2.2.5.2 TAK-007 Phase II Study Design ....................................................................... 64 3.Industry Analysis ...................................................................... 67 3.1 Overview ........................................................................................................... 68 3.2 Legal Requirements and Framework in the U.S. ........................................... 68 3.2.1Clinical Trial Authorization ......................................................................... 68 3.2.2Marketing Authorization ............................................................................. 68 GLOBAL NK CELL THERAPEUTICS MARKET 3.2.3U.S. Food and Drug Administration Guidelines for Biologics License Application (BLA) .......................................................................... 70 3.2.4Post-Authorization Regulations ................................................................. 71 3.3 Legal Requirements and Frameworks in Europe .......................................... 72 3.4 Legal Requirements and Framework in Japan .............................................. 73 3.5 Legal Requirements and Framework in South Korea ................................... 74 3.6 Reimbursement Scenario in the U.S. ............................................................. 76 3.7 Reimbursement Scenario in Europe .............................................................. 78 4 All rights reserved at BIS Research Inc.

  5. 4.Market Dynamics ...................................................................... 80 4.1 Overview ........................................................................................................... 81 4.2 Impact Analysis ............................................................................................... 81 4.3 Market Drivers .................................................................................................. 82 4.3.1Rising Number of Clinical Trials ................................................................ 82 4.3.2Increasing Incidence and Prevalence of Cancer ...................................... 83 4.4 Market Restraints ............................................................................................. 85 4.4.1Lack of Specificity and Poor In Vivo Survival of the NK Cells ................ 85 4.4.2High Cost of Immunotherapy Treatment Associated with Cancer .......... 85 4.5 Market Opportunities ....................................................................................... 86 4.5.1Increasing Funding and Investment .......................................................... 86 4.5.2Rising Number of Partnerships and Collaborations ................................ 88 5.Market Analysis ........................................................................ 90 5.1 Global NK Cell Therapeutics Market (by Therapy Type), $Million, 2024- 2032 ................................................................................................................... 91 5.1.1Overview ...................................................................................................... 91 5.1.2NK Cell Therapy (Unmodified) .................................................................... 93 5.1.3CAR-NK Cell Therapy (Modified) ................................................................ 95 5.1.4NK Cell Engagers ........................................................................................ 99 5.2 Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024-2032........................................................................................................ 102 5.2.1Overview .................................................................................................... 102 GLOBAL NK CELL THERAPEUTICS MARKET 5.2.2AFM13 ......................................................................................................... 104 5.2.3MG4101 ....................................................................................................... 105 5.2.4GTA002 (oNKord) ...................................................................................... 106 5.2.5TAK-007 ...................................................................................................... 107 5.3 Global NK Cell Therapeutics Market (by Indication), $Million, 2024- 2032 ................................................................................................................. 108 5.3.1Overview .................................................................................................... 108 5.3.2Acute Myeloid Leukemia ........................................................................... 109 5 All rights reserved at BIS Research Inc.

  6. 5.3.3Hepatocellular Carcinoma ........................................................................ 111 5.3.4Peripheral T-Cell Lymphoma .................................................................... 113 5.3.5Relapsed or Refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL) .................................................................................................................... 115 5.4 Global NK Cell Therapeutics Market (by Country), $Million, 2024-2032 ... 117 5.4.1Overview .................................................................................................... 117 5.4.2U.S. ............................................................................................................. 119 5.4.3U.K. ............................................................................................................. 121 5.4.4Germany ..................................................................................................... 122 5.4.5France ......................................................................................................... 123 5.4.6Italy ............................................................................................................. 124 5.4.7Spain ........................................................................................................... 125 5.4.8Japan .......................................................................................................... 126 5.4.9South Korea ............................................................................................... 127 6.Market - Competitive Benchmarking & Company Profiles ........ 129 6.1 Competitive Landscape ................................................................................ 130 6.1.1Clinical Developments .............................................................................. 130 6.1.2Regulatory and Legal Activities ............................................................... 131 6.1.3Partnerships and Alliances ...................................................................... 132 6.1.4Funding Activities ..................................................................................... 134 6.1.4.1 Institutional Fundings ..................................................................................... 134 6.1.5Business Expansions ............................................................................... 135 GLOBAL NK CELL THERAPEUTICS MARKET 6.2 Company Profiles .......................................................................................... 136 6.2.1Overview .................................................................................................... 136 6.2.2Affimed N.V. ............................................................................................... 137 6.2.2.1 Company Overview ........................................................................................ 137 6.2.2.2 Role of Affimed N.V. in the Global NK Cell Therapeutics Market .................... 137 6.2.2.3 Key Competitors of the Company ................................................................... 138 6.2.2.4 Financials ....................................................................................................... 139 6.2.2.5 Key Insight about the Financial Health of the Company ................................. 140 6 All rights reserved at BIS Research Inc.

  7. 6.2.2.6 Business Strategies ....................................................................................... 141 6.2.2.7 Analyst Perspective ........................................................................................ 142 6.2.3Century Therapeutics, Inc. ....................................................................... 143 6.2.3.1 Company Overview ........................................................................................ 143 6.2.3.2 Role of Century Therapeutics, Inc. in the Global NK Cell Therapeutics Market ............................................................................................................ 143 6.2.3.3 Key Competitors of the Company ................................................................... 144 6.2.3.4 Financials ....................................................................................................... 144 6.2.3.5 Key Insight about the Financial Health of the Company ................................. 145 6.2.3.6 Business Strategies ....................................................................................... 145 6.2.3.7 Analyst Perspective ........................................................................................ 146 6.2.4Celularity Inc. ............................................................................................. 147 6.2.4.1 Company Overview ........................................................................................ 147 6.2.4.2 Role of Celularity Inc. in the Global NK Cell Therapeutics Market .................. 147 6.2.4.3 Key Competitors of the Company ................................................................... 148 6.2.4.4 Financials ....................................................................................................... 148 6.2.4.5 Key Insight about the Financial Health of the Company ................................. 149 6.2.4.6 Business Strategies ....................................................................................... 150 6.2.4.7 Analyst Perspective ........................................................................................ 150 6.2.5Cytovac A/S ............................................................................................... 152 6.2.5.1 Company Overview ........................................................................................ 152 6.2.5.2 Role of Cytovac A/S in Global NK Cell Therapeutics Market .......................... 152 GLOBAL NK CELL THERAPEUTICS MARKET 6.2.5.3 Key Competitors of the Company ................................................................... 153 6.2.5.4 Analyst Perspective ........................................................................................ 153 6.2.6Dragonfly Therapeutics, Inc. .................................................................... 154 6.2.6.1 Company Overview ........................................................................................ 154 6.2.6.2 Role of Dragonfly Therapeutics, Inc. in the Global NK Cell Therapeutics Market ............................................................................................................ 154 6.2.6.3 Key Competitors of the Company ................................................................... 155 6.2.6.4 Business Strategies ....................................................................................... 156 7 All rights reserved at BIS Research Inc.

  8. 6.2.6.5 Analyst Perspective ........................................................................................ 156 6.2.7Fate Therapeutics, Inc. .............................................................................. 157 6.2.7.1 Company Overview ........................................................................................ 157 6.2.7.2 Role of Fate Therapeutics, Inc. in the Global NK Cell Therapeutics Market ....................................................................................................................... 157 6.2.7.3 Key Competitors of the Company ................................................................... 158 6.2.7.4 Financials ....................................................................................................... 159 6.2.7.5 Key Insight about the Financial Health of the Company ................................. 159 6.2.7.6 Business Strategies ....................................................................................... 160 6.2.7.7 Analyst Perspective ........................................................................................ 160 6.2.8Gamida Cell Ltd. ........................................................................................ 162 6.2.8.1 Company Overview ........................................................................................ 162 6.2.8.2 Role of Gamida Cell Ltd. in the Global NK Cell Therapeutics Market ............. 162 6.2.8.3 Key Competitors of the Company ................................................................... 163 6.2.8.4 Financials ....................................................................................................... 163 6.2.8.5 Key Insight about the Financial Health of the Company ................................. 164 6.2.8.6 Analyst Perspective ........................................................................................ 164 6.2.9GC Cell (GC Biopharma corp.) ................................................................. 165 6.2.9.1 Company Overview ........................................................................................ 165 6.2.9.2 Role of GC Cell (GC Biopharma corp.) in Global NK Cell Therapeutics Market ............................................................................................................ 165 6.2.9.3 Key Competitors of the Company ................................................................... 166 GLOBAL NK CELL THERAPEUTICS MARKET 6.2.9.4 Financials ....................................................................................................... 167 6.2.9.5 Business Strategies ....................................................................................... 167 6.2.9.6 Analyst Perspective ........................................................................................ 168 6.2.10Glycostem Therapeutics B.V. ................................................................... 169 6.2.10.1 Company Overview ........................................................................................ 169 6.2.10.2 Role of Glycostem Therapeutics B.V. in the Global NK Cell Therapeutics Market ............................................................................................................ 169 6.2.10.3 Key Competitors of the Company ................................................................... 170 8 All rights reserved at BIS Research Inc.

  9. 6.2.10.4 Business Strategies ....................................................................................... 170 6.2.10.5 Analyst Perspective ........................................................................................ 171 6.2.11ImmunityBio, Inc. ....................................................................................... 172 6.2.11.1 Company Overview ........................................................................................ 172 6.2.11.2 Role of ImmunityBio, Inc. in the Global NK Cell Therapeutics Market ............. 172 6.2.11.3 Key Competitors of the Company ................................................................... 173 6.2.11.4 Financials ....................................................................................................... 173 6.2.11.5 Key Insight about the Financial Health of the Company ................................. 174 6.2.11.6 Business Strategies ....................................................................................... 175 6.2.11.7 Analyst Perspective ........................................................................................ 175 6.2.12Innate Pharma SA ...................................................................................... 177 6.2.12.1 Company Overview ........................................................................................ 177 6.2.12.2 Role of Innate Pharma SA in the Global NK Cell Therapeutics Market ........... 177 6.2.12.3 Key Competitors of the Company ................................................................... 178 6.2.12.4 Financials ....................................................................................................... 178 6.2.12.5 Key Insight about the Financial Health of the Company ................................. 179 6.2.12.6 Business Strategies ....................................................................................... 179 6.2.12.7 Analyst Perspective ........................................................................................ 180 6.2.13Nkarta, Inc. ................................................................................................. 181 6.2.13.1 Company Overview ........................................................................................ 181 6.2.13.2 Role of Nkarta, Inc. in the Global NK Cell Therapeutics Market ...................... 181 GLOBAL NK CELL THERAPEUTICS MARKET 6.2.13.3 Key Competitors of the Company ................................................................... 182 6.2.13.4 Financials ....................................................................................................... 182 6.2.13.5 Key Insight about the Financial Health of the Company ................................. 183 6.2.13.6 Business Strategies ....................................................................................... 183 6.2.13.7 Analyst Perspective ........................................................................................ 184 6.2.14Sanofi S.A. ................................................................................................. 185 6.2.14.1 Company Overview ........................................................................................ 185 6.2.14.2 Role of Sanofi S.A. in the Global NK Cell Therapeutics Market ...................... 185 6.2.14.3 Key Competitors of the Company ................................................................... 186 9 All rights reserved at BIS Research Inc.

  10. 6.2.14.4 Financials ....................................................................................................... 187 6.2.14.5 Key Insight about the Financial Health of the Company ................................. 189 6.2.14.6 Business Strategies ....................................................................................... 189 6.2.14.7 Analyst Perspective ........................................................................................ 190 6.2.15Takeda Pharmaceutical Company Limited .............................................. 191 6.2.15.1 Company Overview ........................................................................................ 191 6.2.15.2 Role of Takeda Pharmaceutical Company Limited in the Global NK Cell Therapeutics Market ...................................................................................... 191 6.2.15.3 Key Competitors of the Company ................................................................... 192 6.2.15.4 Financials ....................................................................................................... 192 6.2.15.5 Key Insight about the Financial Health of the Company ................................. 193 6.2.15.6 Analyst Perspective ........................................................................................ 194 6.2.16VaxCell Biotherapeutics Co., Ltd. ............................................................ 195 6.2.16.1 Company Overview ........................................................................................ 195 6.2.16.2 Role of VaxCell Biotherapeutics Co., Ltd. in the Global NK Cell Therapeutics Market ...................................................................................... 195 6.2.16.3 Key Competitors of the Company ................................................................... 196 6.2.16.4 Analyst Perspective ........................................................................................ 196 6.3 Emerging Companies .................................................................................... 197 6.3.1Overview .................................................................................................... 197 6.3.2Acepodia Inc. ............................................................................................. 197 6.3.2.1 Company Overview ........................................................................................ 197 GLOBAL NK CELL THERAPEUTICS MARKET 6.3.2.2 Role of Acepodia Inc. in the Global NK Cell Therapeutics Market .................. 197 6.3.2.3 Key Competitors of the Company ................................................................... 198 6.3.2.4 Analyst Perspective ........................................................................................ 198 6.3.3iCell Gene Therapeutics ............................................................................ 199 6.3.3.1 Company Overview ........................................................................................ 199 6.3.3.2 Role of iCell Gene Therapeutics in the Global NK Cell Therapeutics Market ....................................................................................................................... 199 6.3.3.3 Key Competitors of the Company ................................................................... 200 10 All rights reserved at BIS Research Inc.

  11. 6.3.3.4 Analyst Perspective ........................................................................................ 200 6.3.4Senti Biosciences ...................................................................................... 201 6.3.4.1 Company Overview ........................................................................................ 201 6.3.4.2 Role of Senti Biosciences in Global NK Cell Therapeutics Market .................. 201 6.3.4.3 Key Competitors of the Company ................................................................... 202 6.3.4.4 Analyst Perspective ........................................................................................ 202 6.3.5Shoreline Biosciences .............................................................................. 203 6.3.5.1 Company Overview ........................................................................................ 203 6.3.5.2 Role of Shoreline Biosciences in the Global NK Cell Therapeutics Market ..... 203 6.3.5.3 Key Competitors of the Company ................................................................... 204 6.3.5.4 Analyst Perspective ........................................................................................ 204 GLOBAL NK CELL THERAPEUTICS MARKET 11 All rights reserved at BIS Research Inc.

  12. List of Figures Figure 1: Immunotherapies Approved by the U.S. Food and Drug Administration (FDA), 2011-2022 Figure 2: NK Cell Therapeutics Clinical Trials (by Phase), 2022 Figure 3: NK Cell Therapeutics Clinical Trials (by Indication), 2022 Figure 4: Global NK Cell Therapeutics Market Growth Revenue, $Million, 2024-2032 Figure 5: Global NK Cell Therapeutics Market (by NK Cell Therapeutics Type), $Million, 2024, 2025, 2026, and 2032 Figure 6: Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024, 2025, 2026, and 2032 Figure 7: Global NK Cell Therapeutics Market (by Indication), $Million, 2024, 2025, 2026, and 2032 Figure 8: Global NK Cell Therapeutics Market (by Region), $Million, 2024-2032 Figure 9: Global NK Cell Therapeutics Market Segmentation Figure 10: Global NK Cell Therapeutics Market Methodology Figure 11: Primary Research Methodology Figure 12: Epidemiology-Based Approach Figure 13: Types of Immunotherapies Figure 14: Types of NK Cells Figure 15: Academic NK Clinical Milestones Figure 16: Types of NK Cell Therapeutics Figure 17: NK Cell Interacts with Healthy Cell Figure 18: NK Cell Interacts with Target Cell Figure 19: Applications of NK Cell Therapeutics in Disease Areas Figure 20: Global NK Cell Therapeutics Market Growth Revenue, $Million, 2024-2032 GLOBAL NK CELL THERAPEUTICS MARKET Figure 21: Areas of Disruption in Clinical Development Figure 22: NK Cell Therapeutics Clinical Trials (by Phase), 2022 Figure 23: NK Cell Therapeutics Clinical Trials (by Indication), 2022 Figure 24: AFM13 Phase II Clinical Design for Peripheral T-Cell Lymphoma Figure 25: MG4101 Phase II Clinical Design for Hepatocellular Carcinoma, Treatment Group and Control Group Figure 26: MG4101 Phase II Clinical Design for Hepatocellular Carcinoma Figure 27: GTA002 (oNKord) Phase II WiNK Trial Stages for Acute Myeloid Leukemia Figure 28: GTA002 (oNKord) Phase II Clinical Design for Acute Myeloid Leukemia 12 All rights reserved at BIS Research Inc.

  13. Figure 29: TAK-007 Phase II Trial Stages for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) Figure 30: TAK-007 Phase II Clinical Design for Relapsed or Refractory (r/r) B-Cell Non-Hodgkin’s Lymphoma (NHL) Figure 31: Clinical Trial Authorization for NK Cell Therapeutics Figure 32: Process for Obtaining Marketing Authorization Figure 33: Procedures Offered by the Food and Drug Administration (FDA) for Drugs Intended to Treat Serious Health Conditions Figure 34: U.S. Food and Drug Administration Review Timeline Figure 35: EMA Review Timeline Figure 36: South Korea Approval Process from Development to Authorization Figure 37: Reimbursement Scenarios in the U.S. for CAR T-Cell Therapy (Initial and Current Approach) Figure 38: Current Reimbursement Scenario in Europe Figure 39: Impact Analysis of Market Drivers Figure 40: Number of Clinical Trials for NK Cell Therapies (by Year) Figure 41: Number of Clinical Trials for NK Cell Therapies (by Major Players) Figure 42: Global Cancer Incidence, 2017-2018 Figure 43: Cancer Incidence (by Region), 2017-2018 Figure 44: Global NK Cell Therapeutics Market (by Therapy Type) Figure 45: Global NK Cell Therapeutics Market (by Therapy Type), $Million, 2024, 2025, 2026, and 2032 Figure 46: NK Cell Therapy (Unmodified) Market, $Million, 2024-2032 Figure 47: CAR-NK Cell Therapy (Modified) Market, $Million, 2025-2032 Figure 48: NK Cell Engagers Market, $Million, 2026-2032 Figure 49: Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024, 2025, 2026, and GLOBAL NK CELL THERAPEUTICS MARKET 2032 Figure 50: Global Revenue for AFM13, $Million, 2026-2032 Figure 51: Global Revenue for MG4101, $Million, 2026-2032 Figure 52: Global Revenue for GTA002 (oNKordA), $Million, 2024-2032 Figure 53: Global Revenue for TAK-007, $Million, 2025-2032 Figure 54: Global NK Cell Therapeutics Market (by Indication), $Million, 2024, 2025, 2026, and 2032 Figure 55: Global NK Cell Therapeutics Market (by Acute Myeloid Leukemia), $Million, 2024-2032 Figure 56: Global NK Cell Therapeutics Market (by Hepatocellular Carcinoma), $Million, 2026-2032 Figure 57: Global NK Cell Therapeutics Market (by Peripheral T-Cell Lymphoma), $Million, 2026-2032 13 All rights reserved at BIS Research Inc.

  14. Figure 58: Global NK Cell Therapeutics Market (by Relapsed or Refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)), $Million, 2026-2032 Figure 59: Global NK Cell Therapeutics Market (by Region) Figure 60: Global NK Cell Therapeutics Market (by Region), $Million, 2024-2032 Figure 61: Global NK Cell Therapeutics Market (by Country), $Million, 2024-2032 Figure 62: U.S. NK Cell Therapeutics Market, $Million, 2024-2032 Figure 63: U.K. NK Cell Therapeutics Market, $Million, 2024-2032 Figure 64: Germany NK Cell Therapeutics Market, $Million, 2024-2032 Figure 65: France NK Cell Therapeutics Market, $Million, 2024-2032 Figure 66: Italy NK Cell Therapeutics Market, $Million, 2024-2032 Figure 67: Spain NK Cell Therapeutics Market, $Million, 2024-2032 Figure 68: Japan NK Cell Therapeutics Market, $Million, 2024-2032 Figure 69: South Korea NK Cell Therapeutics Market, $Million, 2024-2032 Figure 70: Share of Key Developments and Strategies, January 2019-April 2022 Figure 71: Share of Regulatory and Legal Activities (by Company), January 2019-April 2022 Figure 72: Share of Partnerships and Alliances (by Company), January 2019-April 2022 Figure 73: Share of Funding Activities (by Company), January 2019-April 2022 Figure 74: Share of Business Expansions (by Company), January 2019-April 2022 Figure 75: Affimed N.V.: Preclinical and Clinical Assets Figure 76: Affimed N.V.: Overall Financials, $Million, 2019-2021 Figure 77: Affimed N.V.: Revenue (by Region), $Million, 2019-2021 Figure 78: Affimed N.V.: R&D Expenditure, $Million, 2019-2021 Figure 79: Affimed N.V: R&D Expenditure (by Product), $Million, 2019-2021 GLOBAL NK CELL THERAPEUTICS MARKET Figure 80: Century Therapeutics, Inc.: Preclinical and Clinical Assets Figure 81: Century Therapeutics, Inc.: Overall Financials, $Million, 2020-2021 Figure 82: Century Therapeutics, Inc.: R&D Expenditure, $Million, 2020-2021 Figure 83: Celularity Inc.: Preclinical and Clinical Assets Figure 84: Celularity Inc. Overall Financials, $Million, 2020-2021 Figure 85: Celularity Inc.: Revenue (by Segment), $Million, 2020-2021 Figure 86: Celularity Inc.: R&D Expenditure, $Million, 2020-2021 Figure 87: Cytovac A/S: Preclinical and Clinical Assets Figure 88: Dragonfly Therapeutics, Inc.: Preclinical and Clinical Assets Figure 89: Fate Therapeutics, Inc.: Preclinical and Clinical Assets 14 All rights reserved at BIS Research Inc.

  15. Figure 90: Fate Therapeutics, Inc. Overall Financials, $Million, 2019-2021 Figure 91: Fate Therapeutics, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 92: Gamida Cell Ltd.: Preclinical and Clinical Assets Figure 93: Gamida Cell Ltd. Overall Financials, $Million, 2019-2021 Figure 94: Gamida Cell Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 95: GC Cell (GC Biopharma corp.) Preclinical and Clinical Assets Figure 96: GC Cell (GC Biopharma corp.) Overall Financials, $Million, 2019-2021 Figure 97: Glycostem Therapeutics B.V.: Preclinical and Clinical Assets Figure 98: ImmunityBio, Inc.: Preclinical and Clinical Assets Figure 99: ImmunityBio, Inc.: Overall Financials, $Million, 2019-2021 Figure 100: ImmunityBio, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 101: ImmunityBio, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 102: Innate Pharma SA: Preclinical and Clinical Assets Figure 103: Innate Pharma SA: Overall Financials, $Million, 2019-2021 Figure 104: Innate Pharma SA: R&D Expenditure, $Million, 2019-2021 Figure 105: Nkarta, Inc.: Preclinical and Clinical Assets Figure 106: Nkarta, Inc.: Overall Financials, $Million, 2019-2021 Figure 107: Nkarta, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 108: Sanofi S.A.: Preclinical and Clinical Assets Figure 109: Sanofi S.A.: Overall Financials, $Million, 2019-2021 Figure 110: Sanofi S.A.: Revenue (by Segment), $Million, 2019-2021 Figure 111: Sanofi S.A.: Revenue (by Region), $Million, 2019-2021 Figure 112: Sanofi S.A.: R&D Expenditure, $Million, 2019-2021 GLOBAL NK CELL THERAPEUTICS MARKET Figure 113: Takeda Pharmaceutical Company Limited: Preclinical and Clinical Assets Figure 114: Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2019-2021 Figure 115: Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2019-2021 Figure 116: Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2019-2021 Figure 117: VaxCell Biotherapeutics Co., Ltd.: Preclinical and Clinical Assets Figure 118: Acepodia Inc.: Preclinical and Clinical Assets Figure 119: iCell Gene Therapeutics: Preclinical and Clinical Assets Figure 120: Senti Biosciences: Preclinical and Clinical Assets Figure 121: Shoreline Biosciences: Preclinical and Clinical Assets 15 All rights reserved at BIS Research Inc.

  16. List of Tables Table 1: CAR T-Cell Therapy vs. NK Cell Therapy Table 2: Advantages and Limitations of NK Cell Therapeutics Table 3: Emerging NK Cell Therapeutics Pipeline Table 4: Probable Potential First Entrants to Global NK Cell Therapeutics Market Table 5: Reimbursement Scenario of CAR T-Cell Therapies in EU5 Countries Table 6: Approximate Cost of the Different Types of Immunotherapies Table 7: Funding and Investment Activities of the Companies Table 8: Partnerships and Collaborations of the Companies Table 9: NK Cell Therapy (Unmodified) Pipeline Products Table 10: CAR-NK Cell Therapy (Modified) Pipeline Products Table 11: NK Cell Engagers Pipeline Products Table 12: NK Cell Therapeutics (Pipeline Products) for Acute Myeloid Leukemia Table 13: NK Cell Therapeutics (Pipeline Products) for Hepatocellular Carcinoma Table 14: NK Cell Therapeutics (Pipeline Products) for T-Cell Malignancies and Peripheral T-Cell Lymphoma Table 15: NK Cell Therapeutics (Pipeline Products) for B-Cell Malignancies Table 16: List of Key Competitors of Affimed N.V. Table 17: List of Key Competitors of Century Therapeutics, Inc. Table 18: List of Key Competitors of Celularity Inc. Table 19: List of Key Competitors of Cytovac A/S Table 20: List of Key Competitors of Dragonfly Therapeutics, Inc. Table 21: List of Key Competitors of Fate Therapeutics, Inc. GLOBAL NK CELL THERAPEUTICS MARKET Table 22: List of Key Competitors of Gamida Cell Ltd. Table 23: List of Key Competitors of GC Cell (GC Biopharma corp.) Table 24: List of Key Competitors of Glycostem Therapeutics B.V. Table 25: List of Key Competitors of ImmunityBio, Inc. Table 26: List of Key Competitors of Innate Pharma SA Table 27: List of Key Competitors of Nkarta, Inc. Table 28: List of Key Competitors of Sanofi S.A. Table 29: List of Key Competitors of Takeda Pharmaceutical Company Limited Table 30: List of Key Competitors of VaxCell Biotherapeutics Co., Ltd. 16 All rights reserved at BIS Research Inc.

  17. Table 31: List of Key Competitors of Acepodia Inc. Table 32: List of Key Competitors of iCell Gene Therapeutics Table 33: List of Key Competitors of Senti Biosciences Table 34: List of Key Competitors of Shoreline Biosciences GLOBAL NK CELL THERAPEUTICS MARKET 17 All rights reserved at BIS Research Inc.

  18. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More GLOBAL NK CELL THERAPEUTICS MARKET Know More 18 All rights reserved at BIS Research Inc.

  19. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published, or reproduced, in whole or in part, by any medium or in any form for any purpose, without the written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL NK CELL THERAPEUTICS MARKET 19 All rights reserved at BIS Research Inc.

  20. BIS RESEARCH INC. GLOBAL NK CELL THERAPEUTICS MARKET 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com 20 All rights reserved at BIS Research Inc.

More Related